A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

NCT03356639 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: ASP6981
DRUG: Placebo

Sponsor

Astellas Pharma Global Development, Inc.